Human coronavirus-associated myocarditis is known, and a number of coronavirus disease
19 (COVID-19)–related myocarditis cases have been reported. The pathophysiology of …

Immunotherapies have revolutionized medical oncology following the remarkable and, in
some cases, unprecedented outcomes observed in certain groups of patients with cancer …

Rare immune-mediated cardiac tissue inflammation can occur after vaccination, including
after SARS-CoV-2 mRNA vaccines. However, the underlying immune cellular and molecular …

The response of immune cells in cardiac injury is divided into three continuous phases:
inflammation, proliferation and maturation. The kinetics of the inflammatory and proliferation …

Background: Inflammation is a key component of cardiac disease, with macrophages and T
lymphocytes mediating essential roles in the progression to heart failure. Nonetheless, little …

Myocarditis is the progressive inflammation of the middle layer of the heart followed by a
myocardial injury without ischemic events [1, 2]. The infectious and non-infectious causes of …

Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence worldwide,
already accounting for at least half of all cases of heart failure. As most patients with HFpEF …

In recent years, the myocardium has been rediscovered under the lenses of immunology,
and lymphocytes have been implicated in the pathogenesis of cardiomyopathies with …

Myocardial inflammation can lead to lethal acute or chronic heart failure (HF). T lymphocytes
(T cells), have been reported in the inflamed heart in different etiologies of HF, and more …

Met tyrosine kinase receptor, also known as c-Met, is the HGF (hepatocyte growth factor)
receptor. The HGF/Met pathway has a prominent role in cardiovascular remodelling after …